| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.00B | 6.12B | 6.26B | 6.04B | 5.81B | 4.92B |
| Gross Profit | 2.26B | 2.32B | 2.35B | 2.43B | 2.43B | 2.11B |
| EBITDA | 309.21M | 7.05M | -971.83M | 407.75M | 452.22M | 352.36M |
| Net Income | -2.20M | -101.82M | -1.28B | 90.80M | 164.42M | -26.48M |
Balance Sheet | ||||||
| Total Assets | 5.21B | 5.19B | 5.36B | 6.61B | 6.50B | 6.08B |
| Cash, Cash Equivalents and Short-Term Investments | 237.41M | 165.76M | 125.43M | 201.90M | 211.60M | 111.40M |
| Total Debt | 1.39B | 2.96B | 3.04B | 3.13B | 3.05B | 3.00B |
| Total Liabilities | 4.05B | 4.08B | 4.18B | 4.23B | 4.24B | 4.02B |
| Stockholders Equity | 1.16B | 1.11B | 1.18B | 2.38B | 2.27B | 2.07B |
Cash Flow | ||||||
| Free Cash Flow | 129.61M | 49.68M | -9.88M | 67.98M | 119.11M | 109.06M |
| Operating Cash Flow | 256.52M | 177.67M | 215.72M | 346.00M | 358.21M | 268.62M |
| Investing Cash Flow | -121.82M | -123.90M | -207.44M | -320.32M | -237.08M | -157.19M |
| Financing Cash Flow | -6.30M | -8.75M | -85.35M | -33.84M | -18.78M | -146.61M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
61 Neutral | $13.31B | 66.22 | 59.58% | ― | 9.80% | -46.84% | |
54 Neutral | $669.51M | ― | -35.37% | ― | -4.90% | 50.77% | |
52 Neutral | $824.05M | -271.30 | -0.19% | ― | -3.85% | 97.87% | |
51 Neutral | $283.32M | -1.29 | -67.22% | ― | -8.07% | -2206.16% | |
50 Neutral | $160.75M | -4.58 | -33.59% | ― | -7.61% | -18.41% | |
48 Neutral | $42.14M | -358.82 | -0.38% | 25.20% | -5.07% | -115.50% |
On January 12, 2026, Petco announced the launch of a debt refinancing transaction aimed at extending the maturities on $1.5 billion of its existing term loan, following a $50 million voluntary prepayment made in December 2025 and with the option to make further prepayments under a $100 million board authorization, signaling an effort to optimize its capital structure amid ongoing market uncertainty. In connection with the refinancing, the company reaffirmed its guidance for the fourth quarter and full fiscal year 2025 ending January 31, 2026, projecting net sales to decline 2.5%–2.8% for the year with low single-digit declines in the fourth quarter and forecasting Adjusted EBITDA of $395 million–$397 million for fiscal 2025 and $93 million–$95 million for the quarter, underscoring management’s confidence in operational performance and category resilience despite softer top-line trends.
The most recent analyst rating on (WOOF) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Petco Health and Wellness Company stock, see the WOOF Stock Forecast page.
On November 25, 2025, Petco announced its third-quarter financial results, reporting a 3.1% year-over-year decrease in net sales to $1.5 billion, in line with its outlook. Despite the sales decline, Petco improved its gross profit margin and operating income, and increased its adjusted EBITDA. The company revised its fiscal 2025 earnings outlook upward, indicating a strengthened economic model and setting the stage for growth in 2026. Petco’s strategic focus on profitability and operational transformation is expected to enhance its competitive positioning and stakeholder value.
The most recent analyst rating on (WOOF) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on Petco Health and Wellness Company stock, see the WOOF Stock Forecast page.